ACM Global Receives Top Accreditation Renewal from College of American Pathologists
ACM Global Central Laboratory, a central lab that specializes in delivering high quality testing services designed to optimize clinical trial outcomes, has renewed its College of American Pathologists (CAP) accreditation based on the results of a recent onsite inspection.
ACM Global Central Laboratory
, a central lab that specializes in delivering high quality testing services designed to optimize clinical trial outcomes, has renewed its College of American Pathologists (CAP) accreditation based on the results of a recent onsite inspection.
The College of American Pathology conducted its biennial assessment of ACM U.S. laboratory and pathology operations and found no deficiencies at the company’s laboratory facilities in Rochester, New York. Inspection processes consists of examining quality control procedures and lab records including staff qualifications, equipment, health and safety along with the overall management of the facility. This rigorous process is designed to ensure the highest standard of care for all laboratory patients of central labs worldwide, and is considered equal or more stringent than the U.S. federal government’s own inspection program.
“The CAP survey process is a rigorous, peer-to-peer assessment of our quality and technical proficiency across a comprehensive range of standards. Maintaining this accreditation clearly demonstrates our dedication to high level performance and best practices as a central lab,” said John D’Souza, MD, laboratory director.
To view a complete list of credentials, please visit the site at
www.acmgloballab.com/credentials.aspx
or visit us at
DIA 2013, booth #945
, June 24-28 for more information.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
